AP NEWS

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics: 2018 Worldwide Strategic Business Report - ResearchAndMarkets.com

July 9, 2018

DUBLIN--(BUSINESS WIRE)--Jul 9, 2018--The “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics in US$ Million.

The report profiles 27 companies including many key and niche players such as:

Alcobra Ltd. (Israel) Amarantus Bioscience Holdings, Inc. (US) Amedra Pharmaceuticals LLC (US) Curemark, LLC. (US) Eli Lilly and Company (US) Intellipharmaceutics International, Inc. (US) Janssen Global Services, LLC (US) Mallinckrodt PLC (Ireland) Mylan N.V. (The Netherlands) Neos Therapeutics, Inc. (US) Neurovance, Inc. (US) Noven Pharmaceuticals, Inc. (US) Pfizer Inc. (US) Shire plc (Ireland) Supernus Pharmaceuticals, Inc. (US) Tris Pharma, Inc. (US)

Key Topics Covered

1. MARKET OVERVIEW

ADHD Therapeutics: A Primer ADHD Therapeutics Market Outlook Factors Driving ADHD Therapeutics Market Changes in Insurance Coverage Addition of Formal Guidelines Low Diagnosis Threshold Advancements in Field of Medicine Unmet Needs Launch of Pipeline Drugs Factors Inhibiting ADHD Therapeutics Market Side Effects Related to Use of Stimulants to Treat ADHD Under-diagnosis of ADHD Condition Reduced Availability of Non-Stimulants in Certain Geographies Competitive Landscape Major ADHD Medications Available in the Market ADHD Medications Approved by FDA Patent Validity for Major ADHD Drugs

2. NOTEWORTHY TRENDS IN ADHD THERAPEUTICS MARKET

Biological Psychiatry Gaining Ground Social Media Drives Heightened Awareness Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market Strategic Alliances

3. DEVELOPMENTAL PIPELINE OF ADHD DRUGS

4. ADHD - AN INSIGHT

5. CLINICAL TRIALS

6. PRODUCTS INNOVATIONS/INTRODUCTIONS

7. RECENT INDUSTRY ACTIVITY

8. FOCUS ON SELECT GLOBAL PLAYERS

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 27 (including Divisions/Subsidiaries 28)

The United States (17) Canada (2) Japan (2) Europe (5) The United Kingdom (1)Rest of Europe (4) Middle East (2)

For more information about this report visit https://www.researchandmarkets.com/research/hm335k/attention_deficit?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180709005584/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Mental Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/09/2018 10:45 AM/DISC: 07/09/2018 10:45 AM

http://www.businesswire.com/news/home/20180709005584/en

AP RADIO
Update hourly